25 April 2014 
EMA/339030/2014 
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Invega/ PALIPERIDONE 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
Route(s) of administration: 
Packaging and package size(s): 
See Annex A 
See Annex A 
See Annex A 
Number(s)in the Community Register 
See Annex A 
of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH: 
Janssen-Cilag International N.V. 
Turnhoutseweg 30 
B-2340 Beerse 
BELGIUM 
Procedure  
Procedure number: 
EMEA/H/C/000746/II/0037 
Further to the compliance check performed under Article 23 of Regulation (EC) No° 1901/2006, and 
in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric 
investigation plan PIP P/154/2011. For the purpose of the application of Article 45(3) of Regulation 
(EC) No° 1901/2006, all studies in the agreed paediatric investigation plan PIP P/154/2011 > were 
completed after the entry into force of that Regulation, 
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan.  
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8416 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
  
 
 
 
